We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
Published online by Cambridge University Press: 22 March 2010
Progress in Neurotherapeutics and Neuropsychopharmacology (PNN) represents a new concept in content and in publishing. From a publishing point of view, PNN is a unique combination of print and electronic processing to maximize availability of information. Chapters are solicited continuously and placed online after editing. Online, these chapters are in the complete published and citable format. Annually, chapters are collected into a single volume and published in book form. The chapters are available on the shelf or electronically according to the reader's preference. Moreover, there is minimal delay in conveying the information from the author to the reader. The growing archive of on-line chapters will allow readers to review all of the recent information available for specific diseases, biomarkers, or methodologies.
From the content point of view, PNN has a single focus on therapeutic advances through clinical trials. Clinical trials provide information for evidence-based medicine to advance care of patients. PNN will emphasize double-blind, randomized, controlled trials that provide the highest quality data to guide clinical practice. Each chapter will focus on a single trial or a few related trials and will include an interpretation of how the trial results influence contemporary approaches to practice. Articles relevant to advancing trial methodology will be included. Progress in trial design or trial analyses are an important part of the growing literature on clinical trials. In addition, the integration of biomarkers as surrogate outcome measures in clinical trials is a critically important research area, particularly as disease-modifying agents enter the clinical trials arena.
To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Find out more about the Kindle Personal Document Service.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.
